Answer
Natalizumab’s estimated median elimination half-life is 28.2 days, with a 95th percentile interval for terminal half-life of 11.6–46.2 days.
Sources for this answer
- TYSABRI 300 mg concentrate for solution for infusionBiogen Idec Ltd · emc · SmPC §5.2 Pharmacokinetic properties · Version 43Document updated
Sources checked